Elevated apoptotic cell population in patients with chronic fatigue syndrome: The pivotal role of protein kinase RNA

Journal of Internal Medicine

Volumn 242, Issue 6, 1997, Pages 465-478

  Vojdani, A ^a,b   Ghoneum, M ^b   Choppa, P C ^a   Magtoto, L ^a   Lapp, C W ^c  

^a California   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c Hunter Hopkins Center   (United States)

Author keywords

Apoptosis; Chronic fatigue syndrome; PKR

Indexed keywords

2 AMINOPURINE; ALPHA INTERFERON; HISTONE; MESSENGER RNA; PROTEIN KINASE;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031456383     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.1997.tb00019.x     Document Type: Article

References (61)

1. Fukuda K. Strause SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff AL. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953-9.
2. Schluederberg A. Straus SE, Peterson P. Blumenthal S, Komaroff AL, Spring SB et al. NIH conference chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med 1992; 177: 325-31.
3. Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991; 13: (Suppl. 1): S8-11.
4. Caligiuri M, Murray C, Buchwald D, Levine H, Cheney H, Peterson D et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139: 3306-13.
5. Morrison LJA, Behan WHM, Nehan PO, Changes in natural killer cell phenotypes with patient with post-viral fatigue syndrome. Clin Exp Immunol 1991; 83:441-6.
6. Klimas NG, Salavto FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403-10.
7. Lloyd A. Hickie I, Hickie C, Dwyer J. Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992; 87: 76-9.
8. Chao CC, Janoff EN, Hu S, Thomas K, Gallaghe M. Tsang M et al. Altered cytokine release in peripheral blood mononuclear cell culture from patients with chronic fatigue syndrome. Cytokine 1991; 3: 292-8.
9. Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. Immunologic abnormalities in chronic fatigue syndrome. Med J Aust 1989; 151: 122-4.
10. Gin W, Christiansen FT, Peter JB. Immune function and the chronic fatigue syndrome. Med J Aust 1989; 151: 117-18.
11. Ferbus D, Justesen J, Besancon R, Thang MN. The 2', 5' oligoadenylate synthetase has a multi-functional 2'. 5' nucleotidyl-transferase activity. Biochem Biophys Res Commun 1981; 100:847-56.
12. Mordechai E, Kon N, Henderson EE, Suhadolnik RJ. Activation of the interferon-inducible enzymes. 2'.5' -oligoadenylate synthetase and PKR by human T-cell leukemia virus type I Rex-response element. Virol 1995; 206: 913-22.
13. Zhou A, Hassel BA, Silverman RH, Expression cloning of 2-5A-dependent RNase: A uniquely regulated mediator of interferon action. Cell 1993; 72: 753-65.
14. Floyd-Smith G, Slattary E, Lengyel P. Interferon Action: RNA cleavage pattern of a (2'-5') -oligoadenylate dependent endonuclease. Science 1981; 212: 1020-32.
15. Bisbal C, Martinand C, Silhol M, Lebleu B. Salehzada T. Cloning and characterization of RNase L inhibitor, J Biol Chem 1995; 270: 13308-17.
16. Hovanessian AG. The double-stranded RNA-activated protein kinase induced by interferon: dsRNA-PK. J Interferon Res 1989; 9: 641.
17. Samuel CE. The eIF-2α protein kinases. regulators of translation in eukaryotes from yeast to humans. J Biol Chem 1993; 268: 7603.
18. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992; 257: 1685-9.
19. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG. Tumor suppressor function of the interferon-induced double-stranded RNA-activated, 68,000-Mr protein kinase. Proc Natl Acad Sci USA 1993; 90: 232-6.
20. Lee TG, Tang N, Thompson S, Miller J, Katze MG. The 58,000-Dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a m ember of the tetratricopeptide repeat family of proteins. Mol Cell Biol 1994; 14: 2331-42.
21. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated protein kinases induces apoptosis. Virol 1994; 199: 491-6.
22. Fraser A, McCarthy N, Evan GI. Biochemistry of cell death. Curr Opin in Neurobiol 1996; 6: 71-80.
23. Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death. FASEB J 1993; 6: 2450-55.
24. King KL, Schwartzman RA, Cidlowski JA, Apoptosis in life. death and the cell cycle. Endocrinol & Metabol 1996; 3 (Suppl. A): 93-7.
25. Douglas RG, Martin SJ. The killer and the executioner: how apoptosis controls malignancy. Curr Opin in Immunol 1995; 7: 694-703.
26. Vaux DL, Strasser A, The molecular biology of apoptosis, Proc Natl Acad Sci USA 1996; 93: 2239-44.
27. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against diseases. Tren Pharmacol Sci 1992; 13: 243-51.
28. 12U) in chronic fatigue syndrome. In Vivo 1994; 8: 599-604.
29. Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW. Peterson DL, Henery P et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infections Dis 1994; 18 (Suppl. 1): S96-104.
30. Vojdani A, Ghoneum M. In vivo effect of ascorbic acid on enhacement of human natural killer cell activity. Nutrition Res 1993; 13: 753-64.
31. Meurs E, Chong K, Galabru J, Thomas NSB, Kerr I, Williams BRG, Hovanessian AG. Molecular cloning and characterization of the human double-stranded RNA-activatcd protein kinase induced by interferon. Cell 1990; 62: 379-90.
32. Hovanessian AG, Laurent AG, Chebath J, Galabru, J. Robert N, Svab J. Identification of 69-Kd and 100-Kd forms of 2-5A synthetase in interferon treated human cells by specific monoclonal antibodies. EMBO J 1987; 6: 1273-80.
33. Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplant 1994; 14: 505-9.
34. Pieper RO. Futscher BW, Dong Q, Eills TM, Erickson LC. Comparison of O-6-methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer-human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun 1990; 2: 13-20.
35. Li X, Traganos F, Melamed MR, Darzynkiewich Z. Single step procedure for labeling DNA strand breaks with fluoresccin- or BODIPY-conjugated deoxynucleotides. Detection of apoptosis and BrdUrd incorporation. Cytometry 1995; 20: 172-80.
36. Li X, Traganos F, Melamed MR, Darzynkiewich Z. Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color. Exp Cell Res 1996; 222: 28-37.
37. Darzynkeiwicz Z. Bruno S, Del Bino G, Gorczca W. Hotz M, Lassota P. Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
38. Latham KE, Cosenza S, Reichenbach NL, Mordechai E, Adelson ME, Horvath SE et al. Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA. a stable 2-5A derivative. Oncogene 1996; 12: 827-57.
39. Buffet-Janvresse C. Vannier JP, Laurent AG, Robert N. Hovanessian AG, Enhanced level of double-stranded RNA-dependent protein kinase in peripheral blood mononuclear cells of patients with viral infections. J Interferon Res 1986; 6: 85-96.
40. Onishi Y, Azuma Y, Sato Y. Mizuno Y, Tadakuma T, Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochem Biophys Acta 1993; 1175: 147-54.
41. Markovits J. Larsen AK, Segal-Bendirdjian E, Fosse P. Saucier JM. Gazit A et al. Inhibition of DNA topoisomerase I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochemical Pharmacology 1994; 48: 549-60.
42. Tiwari RK. Kusari J, Kumar R. Sen GC, Gene induction by interferons and double-standed RNA; selective inhibition by 2-aminopurine. Mol Cell Biol 1988; 8: 4289.
43. Hu Y. Conway TW. 2-aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo. J Interferon Res 1993; 13: 323-8.
44. Luca Gusella G. Musso T, Rottschafer SE, Pulkki K, Varesio L. Potential requirement of a functional double-stranded RNA-dependent protein kinase (PKR) for the tumoricidal activation of macrophages by lipopolysaccharide or IFN-αβ. but not IFN-γ. J Immunol 1995; 154: 345-54.
45. Cohen P. The role of protein phosphorylation in neural and hormonal control of cellular activity. Nature 1984; 296: 613-20.
46. Kumar A, Haque J, Lacoste J, Hiscott J. Williams BRG. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc Natl Acad Sci USA 1994; 91: 6288-92.
47. Baeuerle PA, Baltimore D. The physiology of the NF-κB transcription factor. In: Cohen P & Foulkes JG. eds. Molecular Aspects of Cellular Regulation, Hormonal Control Regulation of Gene Transcription. Amsterdam. the Netherlands: Elsevier Science Publishers B.V., 19??; 409-32.
48. Van Huijsduijnen H, Whelan J, Pescini R, Becker-Andre M. Schenk A-M, DeLamarter JF A T cell enhancer cooperates with NF-κB to yield cytokine induction of E-selectin gene transcription in endothelial cells. J Biol Chem 1992; 267: 22385.
49. Baeuerle PA. Baltimore D. NF-κB: Ten years after. Cell 1996; 87: 13-20.
50. Beg AA. Sha WC. Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995; 376: 167-70.
51. Grimm S, Bauer M, Baeucrle PA, Schulze-Osthoff K.d Bcl-2 down-regulate the activity of transcription factor NF-κB induced upon apoptosis. J Cell Biol 1996; 134: 13-23.
52. Jung M. Zhang Y, Lee S, Dritschilo A. Correction of radiation sensitivity in ataxia telengiectasia by truncated lκ-α. Science 1995; 268: 1619-21.
53. Abbadie C, Kabrun N, Bouali E, Smardova J, Stehelin D. Bandenbunder B, Enrietto PJ. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 1993; 75: 899-912.
54. Waring P. DNA fragmentation induced in macrophages by gliotoxin does not require protein synthesis and is preceded by raised inositol triphosphate levels. J Biol Chem 1990; 265: 14476-80.
55. Martin SJ. Lennon SV. Bonham AM, Cotter TG. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 1990; 145: 1859-67.
56. Cotter TG, Lennon SV, Glynn JM, Grenn DR. Microiilament-disrupting agents prevenl the formation of apoptotic bodies in tumor cells undergoing apoptosis. Cancer Res 1992; 52: 997-1005.
57. Song Q, Baxter GD, Kovacs EM, Findik D. Lavin ME. Inhibition of apoplosis in human tumor cells by okadic acid. J Cell Physiol 1992; 153; 550-56.
58. Schreck R. Meier B, Männel DN, Dröge W. Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992; 175: 1181-94.
59. Couldwell WT, Hinton DR, He S. Chen TC, Sebal I, Weiss MH. Law RE, Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Let 1994; 545: 43-6.
60. Evan GI, Wyllie AH. Gilbert CS, Littlewood TD, Land H, Brooks M et al, Induction of apoplosis in fibroblast by c-myc protein. Cell 1992; 69: 119-28.
61. Swanink CMA. Vercoulen JHMM,Galama JMD, Roos MTL. Meyaard L, Van der Ven-Jongekrijg J Lymphocyte subsets, apoptosis and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996; 173: 460-63.